Jeron Bio Changes Name to Jeron Selvein... Will the Second Pharma Research Emerge?

Geron Bio, a PDRN-based bio company, is preparing for a second leap forward by changing its name to Geron Cellvein and specializing as a PDRN bio company with products such as salmon injections.

On the 22nd, Geron Cellvein announced that it has changed its name to Geron Cellvein as the production of export PN fillers will be in full swing by the end of May.

Geron Cellvein's Geron (ZERO TO ONE) implies the creation of something from zero to one. Cellvein is a combination of cell and vein, meaning it suggests a healthy direction for skin cells.

Geron Cellvein will begin full-scale production of export PN fillers by the end of May. These fillers are planned to be exported to Southeast Asia, including Thailand and the Philippines.

Additionally, the Ministry of Food and Drug Safety’s approval process for Cellvein Injection, a pain injection, has been completed, and full-scale sales will begin in June. The pain injection is based on PDRN (salmon sperm extract) and will also be used as a skin booster.

Since the Ministry of Food and Drug Safety has prohibited the use of cosmetic-grade exosomes previously used as skin boosters, Cellvein Injection, a prescription drug, is emerging as the only alternative.

Furthermore, Geron Cellvein plans to introduce prescription drugs such as treatments for periodontitis, pressure ulcers, and wounds, as well as health functional foods using PDRN.

A company official explained, “The regenerative effect of PDRN can be used through various routes including pharmaceuticals, cosmetics, and health functional foods, so we have many pipelines,” adding, “Starting with fillers, pain injections, and skin boosters, we plan to continuously release product lines in the future.”